(R)-Mequitazine

（R）-美喹他嗪

Report date: 2022/07/04 19:38:02

NME

Base Information

Drug Name(R)-Mequitazine

Drug Alias NameV-0162V0162VO-162

ClassificationSmall molecules > Heterocyclic drugs

Mechanisms of ActionMuscarinic acetylcholine receptor M1 antagonistsMuscarinic acetylcholine receptor M3 antagonistsMuscarinic acetylcholine receptor M2 antagonists

TargetsMuscarinic acetylcholine receptor M2Muscarinic acetylcholine receptor M1Muscarinic acetylcholine receptor M3

Therapy Area/IndicationsPulmonary Disease, Chronic ObstructiveAsthma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryBelgiumGermanyFrance

CombinationsNo

Global Highest StatusPending (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesPierre Fabre Ltd

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesPierre Fabre Medicament

Active IndicationsN/A

Inactive IndicationsPulmonary Disease, Chronic ObstructiveAsthma

Other Information

ATC CodeN/A